Usefulness of CD109 expression as a prognostic biomarker in patients with cancer: A systematic review and meta-analysis
- Abstract
- BACKGROUND: It has been revealed that CD109 expression is associated with prognosis in cancer patients, but it remains unclear thus far. Therefore, we performed a meta-analysis in the present study for a better assessment of the prognostic role of CD109 expression in cancer patients. METHODS: Eligible studies were collected through a search of the PubMed, Embase, Cochrane Library, and Scopus databases. The pooled hazard ratio (HR) with 95% confidence interval (CI) was evaluated to reveal the association between CD109 expression and overall survival (OS) in cancer patients. RESULTS: Seven studies with 1583 patients were enrolled. The pooled HR with 95% CI was calculated as 2.31 (95% CI 1.93-2.76, P < .001), suggesting an association between high expression of CD109 and unfavorable OS in cancer patients. CONCLUSION: This analysis indicated that CD109 expression could be used as a prognostic biomarker in cancer patients. This is the first meta-analysis to report the relationship between CD109 expression and prognosis in cancer patients.
- All Author(s)
- H. M. Koh
; H. J. Lee
; D. C. Kim
- Issued Date
- 2021
- Type
- Article
- Keyword
- cancer; CD109; meta-analysis; prognosis
- Publisher
- Lippincott Williams & Wilkins
- ISSN
- 0025-7974
; 1536-5964
- Citation Title
- Medicine
- Citation Volume
- 100
- Citation Number
- 11
- Citation Start Page
- e25006
- Citation End Page
- e25006
- Language(ISO)
- eng
- DOI
- 10.1097/MD.0000000000025006
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/862
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.